Lundbeck pens $2B Alder takeover to boost brain disease pipeline

Lundbeck has struck a deal to buy Alder BioPharmaceuticals for almost $2 billion. The takeover centers on a near-approval anti-CGRP antibody that could address Lundbeck’s need for revenue drivers to mitigate the loss of patent protection on Northera.